Exelixis (NASDAQ:EXEL) Comes up with Positive Results for its Study of Phase 3 of Cobimetinib Drug

745

By Chris Hillman on July 16, 2014 BioPharma

Exelixis, Inc. (NASDAQ:EXEL) is a biopharma company that is committed to the development and commercialization of therapies for treating cancer. Their first product was COMETRIQ. In the advancement of its product, the company managed to establish an integrated and effective infrastructure that covers, from discovering to marketing, the entire continuum of biopharmaceutical development. The company claims its dedication to provide excellence and care for the patients. In their early-stage discoveries, the company came across several compounds that could be potentially used in treating the cancer patients and patients with metabolic diseases. Exelixis, Inc. (NASDAQ:EXEL) established collaborations with world leading biotech and pharmaceutical companies which include Genentech. The collaborations are for the company’s various programs and compounds. The management team of the company is full of experts in business strategy, sales, marketing, finance, clinical development, discovery research, business development and regulatory affairs. All of the individuals work together, to create a value for the company’s stockholders. They also innovate therapy ideas that help transform the treatment of cancer patients. All the team members are dedicated to providing the excellence and care that the company promises its patients.

Exelixis, Inc. (NASDAQ:EXEL) was performing a study by the name of coBRIM. It was a study of the effect of the company’s drug on patients suffering from “BRAF V600 Mutation-Positive Advanced Melanoma”. Exelixis, Inc. (NASDAQ:EXEL)’s drug was combined with Vemurafenib for treating the patients during the course of this study. Genentech is a subsidiary of Roche Holding Ltd. (ADR) (RHHBY). Genentech was collaborating with Exelixis, Inc. (NASDAQ:EXEL) in the study of coBRIM. The results of the study were good news! According to Genentech, the study successfully met with its end-points that are primary. “Progression Free Survival” or PFS is the time period in which the ailment does not get any worse. The target of the study was to see if the combination medication results in an increased PFS. According to the results of the study of coBRIM, the PFS increased significantly in patients that were treated with the combined medicine as opposed to the patients that were treated with the singular Vemurafenib.

See Next Story: New Engine Reduces CO2 Emissions by 50%

coBRIM was a randomized study in which about 500 patients were internationally enrolled. All of the patients were either ailing from the condition BRAF V600 Mutation Positive metastatic melanoma or advanced melanoma. The study was also controlled by a placebo. Study of coBRIM also had end-points that are secondary too. These included duration of response, rate of objective response and other measures. Safety measures were also taken and the life’s quality was ensured.

Genentech will present the results of the data taken from this study. The firm will also begin regulatory filings of the treatment towards the end of this year. Exelixis, Inc. (NASDAQ:EXEL) will see a richer pipeline by the year’s end after it will present the Phase III results of different studies of treating cancers of prostate, renal cell and thyroid gland. Presently, on a year-to-date basis, the company’s value has decreased by 41.5%. However, there is promise in the future considering the success of phase III results of the study.